Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Masanori Atsukawa et al.|Cancers|2020Cited by 54
Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysisMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Hepatology Research|2021Cited by 50
Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinomaMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Hepatology International|2024Cited by 11
Effect of upfront intensive therapy on oncological outcomes in older patients with high tumor burden metastatic castration‐sensitive prostate cancer: A multicenter retrospective studyYuki Miura, Chikara Οhyama, Shingo Hatakeyama et al.|The Prostate|2022Cited by 6